Pentixapharm's PentixaFor Enters Advanced US Clinical Trials

Pentixapharm Holding AG announced that the US National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have initiated an advanced clinical trial for PentixaFor. The trial includes 77 patients and aims to evaluate PentixaFor's efficacy in identifying adrenal tumors via PET scans. This FDA-endorsed Phase II study is led by Dr. Liza Lindenberg and Prof. Dr. Peter Choyke.

PentixaFor targets hormone-secreting adenomas in conditions like primary aldosteronism (PA) and Cushing's syndrome. Primary aldosteronism contributes significantly to secondary hypertension, affecting millions in the US, and identifying its subtypes is crucial for effective treatment. The study's results could enhance global understanding of PentixaFor's capabilities.

Pentixapharm also plans a Phase III study for PentixaFor's use in PA, aiming for US marketing authorization. Dr. Dirk Pleimes, CEO, emphasizes the potential of PentixaFor to advance CXCR4 imaging in adrenal disease diagnostics and manage PA-induced hypertension.